Next Generation News and Research

RSS

HIE leaders convene to discuss prospect of healthcare delivery

Dr. David Kibbe, recognized healthcare futurist and Senior Advisor, American Academy of Family Physicians, headlined Medicity’s Customer Summit last week, which attracted the nation’s most progressive healthcare organizations engaged in health information exchange (HIE) across the largest ecosystem of connected providers nationwide.

12 Feb 2010

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.

12 Feb 2010

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

QIAGEN N.V. and Celera Corporation today announced an agreement under which QIAGEN will distribute a Celera molecular multiplex assay. The assay is the next generation version of QIAGEN’s ResPlex II assay for detection of respiratory pathogens.

From QIAGEN Manchester Limited 11 Feb 2010

Catalysis Foundation for Health to discover new TB biomarkers with $5M Bill & Melinda Gates Foundation grant

The Catalysis Foundation for Health (Catalysis), a 501 (c) (3) non-profit entity dedicated to developing sustainable diagnostics for the developing world, announced today that it has received a $5 million grant from the Bill & Melinda Gates Foundation. The grant money will be used to discover new tuberculosis (TB) biomarkers that can be used to improve diagnostic tests and potentially develop more effective TB treatments.

10 Feb 2010

Fluidigm releases amplicon tagging protocol for Illumina GA II next-generation sequencer

Fluidigm Corporation today announced the release of its amplicon tagging protocol for the Illumina GA II next-generation sequencer. The 48.48 Access Array integrated fluidic circuit (IFC) allows Illumina GA II users to automatically prepare sequencing-ready libraries from 48 individual samples at a time, for as little as $7 (U.S.) per sample.

10 Feb 2010

Medicinal chemistry paper related to the discovery of CUDC-101 published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that a medicinal chemistry paper related to the discovery of CUDC-101, Curis’s HDAC, EGFR and Her2 inhibitor, was published online in the Journal of Medicinal Chemistry and also will be published in an upcoming print version of the journal.

10 Feb 2010

Bulgaria deploys Gemalto' smart cards to secure access to personal health records for military personnel

Gemalto, the world leader in digital security, today announced that Bulgaria has started deploying its smart cards to secure access to personal health records for the country’s military personnel and their family.

10 Feb 2010

Loyola University Chicago offers new research-intensive program for healthcare industry

Registration is underway for Loyola University Chicago's new infectious disease & immunology master's degree program that will prepare graduates for challenging health-related positions in government, research and private industry.

10 Feb 2010

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and Tulane University, today announced a major extension of the collaborative effort to combat viral hemorrhagic fever (VHF), an effort that will generate an additional $800,000 in contract revenue for Corgenix over the life of the contract.

9 Feb 2010

CRT, AstraZeneca announce alliance to develop new anti-cancer drugs

Cancer Research UK's commercialisation and development arm, Cancer Research Technology (CRT), today announced it has teamed up with biopharmaceutical business, AstraZeneca in a major, multi-project alliance, in which around 30 scientists will be focused on creating a stream of new anti-cancer drugs, it is announced today (Sunday).

9 Feb 2010

GIS: Tbx3 gene improves quality of stem cells reprogrammed from differentiated cells

In the 7 Feb. 2010 issue of the journal Nature, scientists at the Genome Institute of Singapore (GIS), report that a genetic molecule, called Tbx3, which is crucial for many aspects of early developmental processes in mammals, significantly improves the quality of stem cells that have been reprogrammed from differentiated cells.

7 Feb 2010

Sorin Group announces first implant of FDA approved Paradym CRT Model 8750 defibrillator

Sorin Group, a global leader in the treatment of cardiovascular disease, announced today U.S. FDA approval and first implant of its next-generation of cardiac resynchronization therapy defibrillator (CRT-D), Paradym™ CRT Model 8750. Featuring a new, state-of-the-art battery technology, Paradym™ CRT delivers 37 Joules, the highest energy of any implantable cardiac defibrillator (ICD) currently available.

6 Feb 2010

New England Biolabs to supply Wellcome Trust Sanger Institute next-generation sequencing library construction reagents

As an important supplier to the Wellcome Trust Sanger Institute, New England Biolabs is pleased to announce that the Sanger Institute will use New England Biolabs as one of its suppliers for next-generation sequencing library construction reagents.

From New England Biolabs 5 Feb 2010

HSS supports Arthritis Foundation's educational campaign for osteoarthritis

Hospital for Special Surgery, (HSS), a world leader in orthopedics and rheumatology, today announced its support of the Arthritis Foundation and Ad Council newly launched campaign, "Moving is the Best Medicine," to raise awareness of osteoarthritis, increase public health education and support breakthrough research.

5 Feb 2010

Medicity's agent-grid technology for health information exchange awarded U.S. patent

Medicity—the leading provider of health information exchange (HIE) solutions that empower physicians, hospitals and communities to improve care coordination, collaboration and achieve meaningful use of health information technology—today announced the U.S. Patent and Trademark Office has awarded the company Patent No. 7,653,634 for its agent-grid technology for health information exchange. This patented technology, which is at the core of Medicity’s Novo Grid, has become the industry standard for seamless electronic health record (EHR) integration and community-wide health information exchange.

5 Feb 2010

San Antonio Methodist Hospital upgrades to Leksell Gamma Knife Perfexion system

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that it has entered into a contract to supply a Leksell Gamma Knife® PerfexionTM system to Methodist Hospital in San Antonio, Texas. This new Perfexion system, the eighth placed by AMS to date, will replace an existing Gamma Knife supplied by AMS and is expected to begin treating patients later this year.

5 Feb 2010

iPSC technology for identifying agents that reprogram human somatic cells receives Notice of Allowance

Fate Therapeutics, Inc. received a Notice of Allowance from the United States Patent and Trademark Office for U.S. Patent Application Number 10/997,146 entitled "Methods for Reprogramming Somatic Cells." Upon issuance, the patent will cover foundational induced pluripotent stem cell (iPSC) technology for identifying agents that enable the reprogramming of human somatic cells, including pluripotency genes, small molecules and biologics.

5 Feb 2010

Lux Biosciences files NDA with FDA and MAA with EMA for approval of voclosporin

Isotechnika Pharma Inc. today announced that its partner, Lux Biosciences, Inc., has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) and a Market Authorization Application (MAA) with the European Medicines Agency (EMA) for voclosporin, under the proposed brand name, LUVENIQ(TM).

4 Feb 2010

IMRIS to acquire NASL

IMRIS Inc. today announced that it has entered into a definitive agreement to acquire NeuroArm Surgical Limited ("NASL"), a privately held company based in Calgary, Alberta, and its magnetic resonance-compatible neurosurgical robot. The companies expect to close the transaction no later than February 8, 2010, subject to the satisfaction of customary closing conditions. IMRIS has also entered into a memorandum of understanding with MacDonald Dettwiler and Associates Limited ("MDA") to create the next generation of the technology.

4 Feb 2010

Flexpoint Sensor Systems focuses on smaller contracts and production orders

Flexpoint Sensor Systems, Inc. http://www.flexpoint.com announced that the Company has modified the business model. In addition to focusing on large contracts in the medical bed and automotive industry, the company is more aggressively focusing on smaller contracts and production orders that produce immediate income for the Company.

4 Feb 2010

Next Generation News and Research

HIE leaders convene to discuss prospect of healthcare delivery

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

QIAGEN N.V. enters into agreement to distribute Celera molecular multiplex assay

Catalysis Foundation for Health to discover new TB biomarkers with $5M Bill & Melinda Gates Foundation grant

Fluidigm releases amplicon tagging protocol for Illumina GA II next-generation sequencer

Medicinal chemistry paper related to the discovery of CUDC-101 published

Bulgaria deploys Gemalto' smart cards to secure access to personal health records for military personnel

Loyola University Chicago offers new research-intensive program for healthcare industry

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

CRT, AstraZeneca announce alliance to develop new anti-cancer drugs

GIS: Tbx3 gene improves quality of stem cells reprogrammed from differentiated cells

Sorin Group announces first implant of FDA approved Paradym CRT Model 8750 defibrillator

New England Biolabs to supply Wellcome Trust Sanger Institute next-generation sequencing library construction reagents

HSS supports Arthritis Foundation's educational campaign for osteoarthritis

Medicity's agent-grid technology for health information exchange awarded U.S. patent

San Antonio Methodist Hospital upgrades to Leksell Gamma Knife Perfexion system

iPSC technology for identifying agents that reprogram human somatic cells receives Notice of Allowance

Lux Biosciences files NDA with FDA and MAA with EMA for approval of voclosporin

IMRIS to acquire NASL

Flexpoint Sensor Systems focuses on smaller contracts and production orders

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News